Bear takes over sales at Scanacs

Scanacs has appointed Frank Baer as its new sales director, effective January 1, 2023. The move brings decades of pharmaceutical experience to the company, which specialises in direct billing software for local pharmacies. Baer joins from the Elac Elysee cooperative, where he previously served as managing director since 2012.

Frank Baer’s career spans over 35 years in the pharmaceutical sector. A qualified sports scientist and business economist, he has held leadership roles at major firms like Schürholz Arzneimittel, Bristol-Myers Squibb, Pohl Boskamp, and Dermapharm. His most recent position was managing director at Elac, which acquired Scanacs out of insolvency and now owns 80 percent of the company.

At Scanacs, Baer will focus on expanding the firm’s direct billing services. The software helps pharmacies gain financial independence by streamlining payment processes. His deep industry connections, including a board seat at the Federal Association of German Pharmacy Cooperatives (BVDAK), are expected to strengthen the company’s sales strategy. Elac’s takeover of Scanacs in 2023 left founder Frank Böhme with a 20 percent stake. Baer’s appointment follows Elac Elysee’s own insolvency proceedings that year, though his exact role there beyond 2023 remains unclear.

Baer’s arrival signals a push to grow Scanacs’ market presence. His expertise in pharmacy networks and direct billing could help the company solidify its position in the sector. The move also reflects Elac’s ongoing influence in the business, despite its own financial challenges.